Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Fesco plans to introduce unmanned ship management systems

9/21/23 FESH

KuibyshevAzot redeemed 24.4% of treasury shares

9/21/23 KAZT

Polymetal is considering expansion into new jurisdictions

9/21/23 POLY

TMK to place an additional issue of 1.5% of shares

9/21/23 TRMK

FedEx reported for 3 months of fiscal year 2024

9/21/23 FDX

Shareholders of Cherkizovo approved dividends for 6 months 2023

9/20/23 GCHE

Nornickel increases marine copper shipments to China

9/20/23 GMKN

Alrosa suspends diamond sales due to weak demand

9/20/23 ALRS

Detsky Mir completed its transformation into a private business

9/20/23 DSKY

The Mastercard announced a quarterly dividend

9/20/23 MA